IL116283A - Pharmaceutical preparations containing estrogen competitors for the treatment of hyperplasia of the prostate - Google Patents

Pharmaceutical preparations containing estrogen competitors for the treatment of hyperplasia of the prostate

Info

Publication number
IL116283A
IL116283A IL11628395A IL11628395A IL116283A IL 116283 A IL116283 A IL 116283A IL 11628395 A IL11628395 A IL 11628395A IL 11628395 A IL11628395 A IL 11628395A IL 116283 A IL116283 A IL 116283A
Authority
IL
Israel
Prior art keywords
alkyl
phenyl
group
hydroxy
aryl
Prior art date
Application number
IL11628395A
Other languages
English (en)
Hebrew (he)
Other versions
IL116283A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL116283A0 publication Critical patent/IL116283A0/xx
Publication of IL116283A publication Critical patent/IL116283A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11628395A 1994-12-14 1995-12-07 Pharmaceutical preparations containing estrogen competitors for the treatment of hyperplasia of the prostate IL116283A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/356,011 US5589482A (en) 1994-12-14 1994-12-14 Benzo-thiophene estrogen agonists to treat prostatic hyperplasia

Publications (2)

Publication Number Publication Date
IL116283A0 IL116283A0 (en) 1996-03-31
IL116283A true IL116283A (en) 2002-02-10

Family

ID=23399729

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11628395A IL116283A (en) 1994-12-14 1995-12-07 Pharmaceutical preparations containing estrogen competitors for the treatment of hyperplasia of the prostate

Country Status (12)

Country Link
US (1) US5589482A (es)
EP (1) EP0716855A2 (es)
JP (1) JPH08231540A (es)
KR (1) KR100190724B1 (es)
CN (1) CN1130063A (es)
AU (1) AU696573B2 (es)
CA (1) CA2165012C (es)
IL (1) IL116283A (es)
MX (1) MX9505249A (es)
MY (1) MY112949A (es)
NZ (1) NZ280667A (es)
ZA (1) ZA9510592B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0801066A1 (en) * 1996-03-12 1997-10-15 Eli Lilly And Company Heterocyclic substituted benzothiophenes and pharmaceutical compositions
CA2218756A1 (en) * 1996-10-25 1998-04-25 Kristin Sue Marron Substituted benzo¢b!thiophene compounds having activity as selective estrogen receptor modulators
US6271227B1 (en) 1997-04-30 2001-08-07 Eli Lilly And Company Antithrombotic Agents
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
WO1999015521A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Benzothiophenes
KR100378937B1 (ko) 1997-10-20 2003-05-09 에프. 호프만-라 로슈 아게 바이사이클릭 키나아제 억제제
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
SK288019B6 (sk) 1999-12-24 2012-11-05 Aventis Pharma Limited Azaindoles derivatives, their use and pharmaceutical composition containing thereof
DE60124616T2 (de) * 2000-05-08 2007-09-13 Pfizer Products Inc., Groton Enzymatische Spaltung von selektiven Modulatoren des Östrogenrezeptors
JP2004503553A (ja) 2000-06-14 2004-02-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 6,5−縮合二環式複素環
EP1210951B1 (en) * 2000-11-30 2005-02-02 Pfizer Products Inc. Composition containing estrogen agonists/antagonists and testosterone for treating a decline in the level of the hormone testosterone
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
ATE323702T1 (de) 2002-08-06 2006-05-15 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
BRPI0511874A (pt) 2004-06-09 2008-01-15 Glaxo Group Ltd derivados da pirrolopiridina
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
NZ553329A (en) 2004-07-22 2010-09-30 Ptc Therapeutics Inc Thienopyridines for treating hepatitis C
KR101319675B1 (ko) * 2008-09-29 2013-10-22 일라이 릴리 앤드 캄파니 골관절염의 치료를 위한 선택적 에스트로겐 수용체 조절자
EP2503188B1 (de) * 2011-03-25 2015-01-21 NAF Neunkirchener Achsenfabrik AG Schaltzylinder für eine Antriebseinrichtung, insbesondere für eine selbstfahrende Arbeitsmaschine, Antriebseinrichtung, Arbeitsmaschine sowie Verfahren zum Betreiben einer Arbeitsmaschine
SG11201505697VA (en) 2013-02-19 2015-09-29 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
JP6549735B2 (ja) 2015-06-09 2019-07-24 アッヴィ・インコーポレイテッド 核内受容体調節剤
KR102542698B1 (ko) * 2022-04-05 2023-06-14 주식회사 베노바이오 신규한 벤조사이오펜 유도체 및 bet 억제제로서의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
IL65378A (en) * 1981-04-03 1986-02-28 Lilly Co Eli Process for preparing 3-(4-aminoethoxybenzoyl)benzo-(b)thiophenes
AU555658B2 (en) * 1981-04-03 1986-10-02 Eli Lilly And Company Benzothiophene compounds
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4358593A (en) * 1981-04-03 1982-11-09 Eli Lilly And Company Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
GB8311678D0 (en) * 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
US4970237A (en) * 1987-03-20 1990-11-13 Yale University Use of clomiphene to increase bone mass in premenopausal women
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
DE4117512A1 (de) * 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5147880A (en) * 1991-07-22 1992-09-15 Eli Lilly And Company Benzo[a]fluorene compounds
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5196435A (en) * 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US8135386B2 (en) * 2008-07-09 2012-03-13 Telefoanktebolaget L M Ericsson (Publ) Method and apparatus for instance identifier based on a unique device identifier

Also Published As

Publication number Publication date
NZ280667A (en) 2000-08-25
EP0716855A3 (es) 1996-07-10
CA2165012C (en) 1999-03-16
EP0716855A2 (en) 1996-06-19
ZA9510592B (en) 1997-06-13
JPH08231540A (ja) 1996-09-10
CA2165012A1 (en) 1996-06-15
CN1130063A (zh) 1996-09-04
AU696573B2 (en) 1998-09-10
MY112949A (en) 2001-10-31
AU4041295A (en) 1996-06-20
KR100190724B1 (ko) 1999-06-01
IL116283A0 (en) 1996-03-31
US5589482A (en) 1996-12-31
MX9505249A (es) 1997-01-31
KR960021020A (ko) 1996-07-18

Similar Documents

Publication Publication Date Title
IL116283A (en) Pharmaceutical preparations containing estrogen competitors for the treatment of hyperplasia of the prostate
CA2195093C (en) Use of droloxifene for the treatment of prostatic diseases, endometriosis and obesity
US5470883A (en) Method of treating peripheral vasoconstriction with tamoxifen citrate
SI9600004A (en) Estrogene agonists/antagonists
PT652000E (pt) Metodos para a inibicao de angiogenese e doencas angiogenicas
JPH10511962A (ja) 婦人科疾患の治療または予防用の医薬組成物の製造への3,4−ジフェニルクロマンの使用
TW467909B (en) 2-arylbenzo[b]thiophenes useful for the treatment of estrogen deprivation syndrome
PT659413E (pt) Inibicao de problemas do cns em mulheres pos-menopausicas
KR20040030788A (ko) 요실금 치료를 위한 아릴(또는 헤테로아릴)아졸릴카르비놀 유도체
CZ217298A3 (cs) Použití 3,4-difenyl chromanů pro výrobu farm. prostředku
PL190723B1 (pl) Zastosowanie swoistego antagonisty receptora 5HT2do wytwarzania leków korzystnych w leczeniu zespołu snu z bezdechem
HUT71337A (en) Pharmaceutical compositions for inhibiting turner's syndrome containing 2-phenyl-3-aroyl-benzothiophene derivatives and process for their preparation
JPH11506787A (ja) カルシウムチャンネルの調節
IL156170A (en) Use of 1-phenyl-dimethylaminopropane compounds for the treatment of urinary incontinence
JP5313686B2 (ja) 失禁治療方法
NZ538924A (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
JP2001048805A (ja) 骨粗鬆症、心臓血管疾患および胸部ガンを治療し予防する治療薬
US5840747A (en) Calcium channel antagonists
JP4384388B2 (ja) 1,2−エタンジオール誘導体またはその塩を含有する切迫性尿失禁の治療薬
CA2351674A1 (en) Use of a 5ht2a and 5ht2a/c receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways
AU709606B2 (en) Use of droloxifene for the treatment of prostatic diseases endometriosis and obesity
MXPA96003819A (es) Tratamiento de tinnitus empleando agentes neuroprotectores
MXPA97009542A (es) Modulacion de los canales de calcio
PT771201E (pt) Metodos para inibir a hiperplasia endometrica primaria
AU7993998A (en) Droloxifene for prevention of breast cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees